CAMBRIDGE, Mass.--Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that Elisabet de los Pinos, founder and CEO, will present a company overview at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2016 Annual Meeting (OIS@AAO) in Chicago.
The presentation will take place during the Company Showcase on Thursday, October 13, 2016, at 11 a.m. EST.
About Aura Biosciences
Aura Biosciences is developing a new class of therapies to target and selectively destroy tumor cells. Its lead program in ocular melanoma, developed under a CRADA with the National Cancer Institute (NCI), has been granted orphan drug status by the US Food and Drug Administration. For more information, visit www.aurabiosciences.com.
Ann Stanesa, 617-230-0347
Ten Bridge Communications